$2.14
0.70% yesterday
Nasdaq, Sep 05, 10:00 pm CET
ISIN
US2936021086
Symbol
ENSC

Ensysce Biosciences Inc Stock price

$2.14
-0.10 4.26% 1M
-2.97 58.19% 6M
-6.01 73.77% YTD
-3.49 62.04% 1Y
-1,473.87 99.86% 3Y
-38,301.87 99.99% 5Y
-34,737.87 99.99% 10Y
-34,737.87 99.99% 20Y
Nasdaq, Closing price Fri, Sep 05 2025
-0.02 0.70%
ISIN
US2936021086
Symbol
ENSC
Industry

Key metrics

Basic
Market capitalization
$6.3m
Enterprise Value
$3.5m
Net debt
positive
Cash
$3.1m
Shares outstanding
1.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.0 | 2.3
EV/Sales
0.6 | 1.3
EV/FCF
negative
P/B
2.1
Financial Health
Equity Ratio
66.3%
Return on Equity
-215.3%
ROCE
-240.5%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$6.2m | $2.8m
EBITDA
- | $-22.7m
EBIT
$-6.9m | $-13.4m
Net Income
$-6.8m | $-7.0m
Free Cash Flow
$-5.8m
Growth (TTM | estimate)
Revenue
255.4% | -46.2%
EBITDA
- | -
EBIT
31.4% | -99.1%
Net Income
41.0% | 12.0%
Free Cash Flow
45.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -811.0%
EBIT
-110.1%
Net
-109.5% | -250.5%
Free Cash Flow
-93.2%
More
EPS
$-4.9
FCF per Share
$-3.5
Short interest
14.4%
Employees
8
Rev per Employee
$650.0k
Show more

Is Ensysce Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Ensysce Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Ensysce Biosciences Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Ensysce Biosciences Inc forecast:

Buy
86%
Hold
14%

Financial data from Ensysce Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
6.22 6.22
255% 255%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.75 4.75
8% 8%
76%
- Research and Development Expense 8.33 8.33
27% 27%
134%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -6.85 -6.85
31% 31%
-110%
Net Profit -6.82 -6.82
41% 41%
-110%

In millions USD.

Don't miss a Thing! We will send you all news about Ensysce Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ensysce Biosciences Inc Stock News

Neutral
Accesswire
2 days ago
~ Experts Spotlight TAAP™ and MPAR® as Next-Generation Solutions for Severe Pain ~ SAN DIEGO, CA / ACCESS Newswire / September 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today shared key takeaways from its standing-room-...
Neutral
Accesswire
18 days ago
~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~ ~ Ensysce Biopharma Leader to Deliver Opening Remarks and Present Case Study on Launching Successful Brands ~ SAN DIEGO, CA / ACCESS Newswire / August 19, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company pioneeri...
Neutral
GlobeNewsWire
22 days ago
New York, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC). The update note includes information on Ensysce Biosciences' business updates, management commentary, financial results, valuation, and risks.
More Ensysce Biosciences Inc News

Company Profile

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on proprietary technology platforms to develop safer prescription drugs. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms, are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company is headquartered in La Jolla, CA.

Head office United States
CEO D. Kirkpatrick
Employees 8
Founded 2003
Website ensysce.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today